Daniell Richard
SEC CIK 1726096 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | EVP, European Commercial | 55.8K | — | $22.19M | 32 | 2022-02-09 | 2026-05-05 |
Most active insiders at TEVA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Francis Richard D | Pres, CEO | — | $31.26M |
| 2 | MIGNONE ROBERTO | Dir | — | $22.82M |
| 3 | Kalif Eliyahu Sharon | EVP, CFO | — | $20.72M |
| 4 | Sabag Mark | See "Remarks" | — | $13.15M |
| 5 | Daniell Richard | EVP, European Commercial | — | $12.08M |
| 6 | Hughes Eric A | See "Remarks" | — | $4.17M |
| 7 | Fox Christine | EVP, U.S. Commercial | — | $2.75M |
| 8 | Lippman Evan | EVP, Business Development | — | $2.16M |
| 9 | Weiss Amir | CAO | — | $1.41M |
| 10 | Shields Matthew | EVP, Gbl Ops | — | $1.40M |
Transactions 32
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 16:01 | 2026-05-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, Europe Commercial | S - Sale | $35.40 | -30.0K | 55.8K | -35% | -$1.06M | |
| DT | 2026-03-09 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $31.67 | -17.3K | 85.8K | -17% | -$547.7K |
| DT | 2026-03-09 | 2026-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, Europe Commercial | M - OptEx | — | +17.3K | 103.0K | +20% | — |
| DMT | 2026-03-06 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, Europe Commercial | M - OptEx | — | +54.0K | 156.6K | +53% | — |
| DMT | 2026-03-06 | 2026-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $32.66 | -91.3K | 123.1K | -43% | -$2.98M |
| DMT | 2026-03-05 | 2026-03-03 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, Europe Commercial | M - OptEx | — | +203.7K | 189.9K | New | — |
| DMT | 2026-03-05 | 2026-03-03 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, Europe Commercial | S - Sale+OE | $32.36 | -129.0K | 48.4K | -73% | -$4.17M |
| DM | 2025-12-11 | 2025-12-09 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | $18.40 | +115.5K | 163.9K | +239% | +$2.12M |
| D | 2025-12-11 | 2025-12-09 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $28.68 | -115.5K | 48.4K | -70% | -$3.31M |
| DMT | 2025-03-07 | 2025-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $15.90 | -71.0K | 96.8K | -42% | -$1.13M |
| DT | 2025-03-07 | 2025-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +22.6K | 119.3K | +23% | — |
| DMT | 2025-03-06 | 2025-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +237.1K | 33.5K | New | — |
| DMT | 2025-03-06 | 2025-03-04+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $15.79 | -140.4K | 96.8K | -59% | -$2.22M |
| DMT | 2025-03-05 | 2025-03-03+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $16.06 | -62.2K | 0 | -100% | -$999.7K |
| DT | 2025-03-05 | 2025-03-03 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +62.2K | 62.2K | New | — |
| 2024-08-13 | 2024-08-12 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale | $17.30 | -98.9K | 0 | -100% | -$1.71M | |
| DMT | 2024-03-07 | 2024-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $13.52 | -48.6K | 98.9K | -33% | -$657.5K |
| DMT | 2024-03-07 | 2024-03-05 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +77.8K | 92.3K | +535% | — |
| DMT | 2024-03-05 | 2024-03-03+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +95.8K | 132.0K | +264% | — |
| DMT | 2024-03-05 | 2024-03-04 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $13.34 | -95.8K | 69.8K | -58% | -$1.28M |
| DT | 2024-03-01 | 2024-02-28 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +20.6K | 90.4K | +30% | — |
| DT | 2024-03-01 | 2024-02-28 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $13.12 | -20.6K | 69.8K | -23% | -$270.3K |
| M | 2023-03-08 | 2023-03-06+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale | $9.55 | -72.0K | 69.8K | -51% | -$688.0K |
| DM | 2023-03-07 | 2023-03-04+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +72.0K | 119.2K | +153% | — |
| DM | 2023-03-02 | 2023-02-28 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $9.89 | -44.3K | 43.2K | -51% | -$437.7K |
| DM | 2023-03-02 | 2023-02-28 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +70.8K | 63.8K | New | — |
| DM | 2022-03-08 | 2022-03-04+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +81.9K | 36.2K | New | — |
| DM | 2022-03-08 | 2022-03-04+ | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $7.44 | -59.0K | 20.3K | -74% | -$438.5K |
| D | 2022-03-02 | 2022-02-28 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $8.14 | -20.6K | 20.3K | -50% | -$167.7K |
| D | 2022-03-02 | 2022-02-28 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +20.6K | 40.9K | +102% | — |
| D | 2022-02-10 | 2022-02-09 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | M - OptEx | — | +13.1K | 33.4K | +65% | — |
| D | 2022-02-10 | 2022-02-09 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Daniell Richard | EVP, European Commercial | S - Sale+OE | $9.06 | -13.1K | 20.3K | -39% | -$119.0K |
Purchase Sale Sale after option exercise All abbreviations